Savara Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Savara Inc Unternehmen

Savara Inc. is a clinical-stage biopharmaceutical company, which is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. Molgramostim nebulizer solution is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the molgramostim aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.

Savara Inc Informationen



BörsenkürzelSVRA

Name des UnternehmensSavara Inc

IPO-datumJun 25, 2001

CEOMr. Matthew (Matt) Pauls, J.D.

Anzahl der mitarbeiter59

WertpapierartOrdinary Share

GeschäftsjahresendeJun 25

Addresse6836 Bee Cave Road

StadtAUSTIN

BörseNASDAQ Global Select Consolidated

LandUnited States of America

Postleitzahl78746

Telefon151285113796

Websitehttps://savarapharma.com/

BörsenkürzelSVRA

IPO-datumJun 25, 2001

CEOMr. Matthew (Matt) Pauls, J.D.

Führungskräfte von Savara Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. David A. Ramsay

Independent Director

2.47M

-0.70%

Dr. Joseph S. (Joe) Mccracken, Ph.D.

Lead Independent Director

220.84K

+4.74%

Ms. Anne Erickson

Chief Business Officer

194.99K

+72.18%

Mr. Braden Parker

Chief Commercial Officer

105.00K

+23.53%

Mr. Robert Matthew (Rob) Lutz

Chief Operating Officer

101.74K

+64.79%

Mr. Nevan Charles Elam, J.D.

Independent Director

--

Mr. Richard J. (Rick) Hawkins

Independent Director

--

Mr. David L. Lowrance, CPA

Chief Financial and Administrative Officer, Secretary

--

Mr. Matthew (Matt) Pauls, J.D.

Chairman of the Board, Chief Executive Officer

--

Dr. Raymond Dennis (Ray) Pratt, M.D.

Chief Medical Officer

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. David A. Ramsay

Independent Director

2.47M

-0.70%

Dr. Joseph S. (Joe) Mccracken, Ph.D.

Lead Independent Director

220.84K

+4.74%

Ms. Anne Erickson

Chief Business Officer

194.99K

+72.18%

Mr. Braden Parker

Chief Commercial Officer

105.00K

+23.53%

Mr. Robert Matthew (Rob) Lutz

Chief Operating Officer

101.74K

+64.79%

Mr. Nevan Charles Elam, J.D.

Independent Director

--

Umsatzaufteilung

Keine Daten

Keine Daten

Nach Geschäftsbereich

Nach Region

Keine Daten

Aktionärsstatistik

Aktualisiert: Sun, Nov 2

Aktionäre

Aktionärstypen

Aktionäre

Anteil

New Enterprise Associates (NEA)

12.44%

Bain Capital Life Sciences Investors, LLC

8.95%

Deerfield Management Company, L.P.

6.90%

TCG Crossover Management, LLC

6.29%

Frazier Life Sciences Management, L.P.

5.83%

Andere

59.59%

Aktionäre

Anteil

New Enterprise Associates (NEA)

12.44%

Bain Capital Life Sciences Investors, LLC

8.95%

Deerfield Management Company, L.P.

6.90%

TCG Crossover Management, LLC

6.29%

Frazier Life Sciences Management, L.P.

5.83%

Andere

59.59%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

29.98%

Hedge Fund

20.01%

Venture Capital

18.26%

Investment Advisor/Hedge Fund

14.30%

Private Equity

5.83%

Corporation

3.46%

Individual Investor

2.45%

Research Firm

0.47%

Bank and Trust

0.27%

Andere

4.97%

Institutionelle Beteiligung



Aktualisiert: Wed, Oct 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q3

286

169.85M

86.94%

-21.45M

2025Q2

295

181.81M

105.19%

-8.48M

2025Q1

306

176.74M

102.29%

-9.64M

2024Q4

294

173.80M

101.27%

-5.45M

2024Q3

274

169.68M

103.28%

+3.87M

2024Q2

257

157.29M

95.89%

+28.15M

2024Q1

230

131.01M

94.21%

-92.17K

2023Q4

197

123.19M

91.03%

-2.15M

2023Q3

177

120.11M

89.27%

+14.67M

2023Q2

170

92.45M

81.05%

-2.68M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

New Enterprise Associates (NEA)

24.47M

14.16%

--

Jun 30, 2025

Bain Capital Life Sciences Investors, LLC

17.60M

10.18%

--

Jun 30, 2025

Deerfield Management Company, L.P.

7.96M

4.61%

--

Jun 30, 2025

TCG Crossover Management, LLC

12.36M

7.15%

--

Jun 30, 2025

Frazier Life Sciences Management, L.P.

11.46M

6.63%

--

Jun 30, 2025

Vestal Point Capital, LP

11.02M

6.37%

+15.00K

+0.14%

Jun 30, 2025

VR Adviser, LLC

8.88M

5.14%

+5.63M

+172.72%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

8.54M

4.94%

-164.33K

-1.89%

Jun 30, 2025

Nantahala Capital Management, LLC

8.33M

4.82%

+250.00K

+3.10%

Jun 30, 2025

The Vanguard Group, Inc.

8.43M

4.88%

+334.73K

+4.13%

Jun 30, 2025

Verbundene ETFs



Aktualisiert: Thu, Nov 6

Name

Anteil

Virtus LifeSci Biotech Clinical Trials ETF

1.14%

Texas Capital Texas Small Cap Equity Index ETF

0.21%

iShares Micro-Cap ETF

0.08%

Invesco Nasdaq Biotechnology ETF

0.06%

ProShares Ultra Nasdaq Biotechnology

0.06%

Texas Capital Texas Equity Index ETF

0.05%

iShares Biotechnology ETF

0.03%

iShares Russell 2000 Growth ETF

0.03%

ProShares UltraPro Russell2000

0.01%

iShares Morningstar Small-Cap ETF

0.01%

Virtus LifeSci Biotech Clinical Trials ETF

Anteil1.14%

Texas Capital Texas Small Cap Equity Index ETF

Anteil0.21%

iShares Micro-Cap ETF

Anteil0.08%

Invesco Nasdaq Biotechnology ETF

Anteil0.06%

ProShares Ultra Nasdaq Biotechnology

Anteil0.06%

Texas Capital Texas Equity Index ETF

Anteil0.05%

iShares Biotechnology ETF

Anteil0.03%

iShares Russell 2000 Growth ETF

Anteil0.03%

ProShares UltraPro Russell2000

Anteil0.01%

iShares Morningstar Small-Cap ETF

Anteil0.01%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten